Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioChemics has completed a 14-day Phase 2 study in Switzerland demonstrating the efficacy of transdermal ibuprofen-VALE cream, BC-IBU-CH-001, for the treatment of osteoarthritis (OA).
Subscribe to our email newsletter
The study looks at the efficacy of the drug as well as continuing to look at the safety profile established in the Phase 1 trial.
BC-IBU-CH-001 is a transdermal preparation containing 10% ibuprofen.
Results from the multicenter, randomized study showed that patients with OA of the knee treated twice daily with the ibuprofen-VALE preparation on the knee demonstrated substantial improvement in pain.
BioChemics president and CEO John Masiz said the results in less systemic exposure to active drug and combined with avoidance of gastrointestinal system could translate to fewer side effects.